Implementation of a Multiple Intervention to Promote Healthy Lifestyles in Patients With Depression

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age55-80
SponsorIRCCS Centro San Giovanni di Dio Fatebenefratelli

About this trial

This clinical trial aims to investigate whether an integrative approach combining education on the Mediterranean diet and physical activity (PA) can significantly reduce depressive symptomatology in individuals with major depressive disorder. The study will evaluate changes in depressive symptoms and assess biological modulations, including alterations in the gut microbiota and inflammatory markers, resulting from the PA intervention.

Participants will be randomized into two arms: the active control group will attend a series of lessons focused on the Mediterranean diet, while the experimental group will participate in the same dietary lessons combined with a structured PA program of 12 weeks.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Primary diagnosis of depression (DSM-5 criteria, American Psychiatric Association 2013).

Depressive symptoms assessed using MADR, BDI, or ZDR scales.

Ability to provide written informed consent.

Self-reported moderate-intensity leisure physical activity of less than 150 minutes per week.

Disqualifiers

Patients with severe psychopathology.

Medical contraindications to physical activity.

Orthopedic problems or other conditions limiting physical fitness assessment or currently pregnant.

Patients who underwent antibiotic/anti-inflammatory treatments in the last 3 months

Trial design

Design model

Parallel

Treatments tested in this trial

  • Mediterranean diet lessons program

    Behavioral

    Participants will attend five one-hour lessons delivered by qualified professionals to learn about foods that have a positive impact on cognitive function and how to incorporate them into their dietary regimen.

  • Physical activity

    Behavioral

    Participants will undergo a 12-week physical exercise program guided by specified personal trainers.

Treatment groups

120 Participants
are divided into 2 treatment groups
Group A: Control GroupActive comparator 1 intervention
Group B: Experimental GroupExperimental treatment 2 interventions

Trial outcomes

Primary outcomes

1

MADR Scale for Depression

The Montgomery-Åsberg Depression Rating Scale (MADRS) is a clinician-administered scale designed to assess the severity of depressive symptoms. It consists of 10 items, each rated on a scale from 0 to 6, yielding a total score ranging from 0 to 60. Higher scores indicate greater severity of depression, meaning a worse clinical outcome.

Time frame
Baseline (day 1); Week 6 (up to 6 weeks, mid-treatment); Week 12 (up to 12 weeks, end of treatment).
2

Beck Depression Inventory - II

The Beck Depression Inventory (BDI) is a self-report questionnaire used to assess the presence and severity of depressive symptoms. It comprises 21 items, each rated on a scale from 0 to 3, resulting in a total score ranging from 0 to 63. Higher scores reflect more severe depressive symptoms, indicating a worse clinical outcome.

Time frame
Baseline (day 1); Week 6 (up to 6 weeks, mid-treatment); Week 12 (up to 12 weeks, end of treatment).
3

Zung Self-Rating Depression Scale

The Zung Self-Rating Depression Scale (ZRS) is a self-administered questionnaire designed to assess the level of depressive symptoms in individuals. It consists of 20 items, each rated on a scale from 1 to 4, based on how often symptoms are experienced. The raw total score ranges from 20 to 80, which is often converted to an index score (ranging from 25 to 100) by multiplying the raw score by 1.25. Higher scores indicate more severe depression

Time frame
Baseline (day 1); Week 6 (up to 6 weeks, mid-treatment); Week 12 (up to 12 weeks, end of treatment).
4

Personal and Social Performance Scale

The Personal and Social Performance Scale (PSP) is a clinician-rated instrument used to assess personal and social functioning in individuals with mental disorders. The total score ranges from 1 to 100, with higher scores indicating better functioning and a more favorable clinical outcome.

Time frame
Baseline (day 1); Week 6 (up to 6 weeks, mid-treatment); Week 12 (up to 12 weeks, end of treatment).

Secondary outcomes

1

Immunitary-related factors levels

Plasma/serum levels of cytokines

Time frame
Baseline (day 1); Week 12 (up to 12 weeks, end of treatment).
2

Gut Microbiome Composition

Time frame
Baseline (day 1); Week 12 (up to 12 weeks, end of treatment).

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: